LUND, Sweden, April 17, 2026 (GLOBE NEWSWIRE) -- Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announces that it ...
Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard's lead asset AT-108 into Phase 1 clinical development -- AT-108 is a transformative immunotherapy that ...
Creative Biogene is proud to announce the launch of its innovative iPSC RNA reprogramming products, specifically designed to enhance the efficiency and safety of iPSC generation.
On the one hand, more efficient reprogramming could, if poorly controlled, increase the chance of generating cells with unintended self renewal properties. On the other, precise control over gene ...
Prize winner’s research reprograms tumor cells to trigger antitumor immunity Cancer immunotherapies, such as checkpoint inhibitors and CAR-T cells, have revolutionized cancer treatment and ...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced positive data from its HT-VA study, conducted under its Cooperative Research and Development ...
Scientists at the MRC Laboratory of Medical Sciences (LMS) have discovered a DNA-based “dimmer switch” that regulates the activity of a critical developmental gene, Cdx2. This work could pave the way ...
Scientists at the Salk Institute for Biological Studies and Sanford Burnham Prebys explore genetic factors in separate papers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results